Michel Marre
A5088350286- Diabetes Treatment and Management
- Diabetes Management and Research
- Blood Pressure and Hypertension Studies
- Chronic Kidney Disease and Diabetes
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Pancreatic function and diabetes
- Metabolism, Diabetes, and Cancer
- Diet and metabolism studies
- Genetic Associations and Epidemiology
- Diabetes and associated disorders
- Hormonal Regulation and Hypertension
- Pharmacology and Obesity Treatment
- Liver Disease Diagnosis and Treatment
- Diet, Metabolism, and Disease
- Renin-Angiotensin System Studies
- Lipoproteins and Cardiovascular Health
- Birth, Development, and Health
- Cardiovascular Function and Risk Factors
- Peripheral Artery Disease Management
- Retinal Diseases and Treatments
- Advanced Glycation End Products research
- Diabetic Foot Ulcer Assessment and Management
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Adipokines, Inflammation, and Metabolic Diseases
- Dialysis and Renal Disease Management
Université Paris Cité
2016-2025
Inserm
2016-2025
Clinique Ambroise Paré
2019-2025
Institut Necker Enfants Malades
2022-2025
Sorbonne Paris Cité
2013-2024
Centre National de la Recherche Scientifique
2000-2024
South Westphalia University of Applied Sciences
2022-2023
Université Claude Bernard Lyon 1
2013-2022
Hôpital Bichat-Claude-Bernard
2013-2022
Centre de Recherche des Cordeliers
2013-2022
In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain.We randomly assigned 11,140 diabetes to undergo either standard or control, defined as use gliclazide (modified release) plus other drugs required achieve a glycated hemoglobin value 6.5% less. Primary end points were composites major macrovascular events (death from cardiovascular causes, nonfatal myocardial infarction, stroke) and microvascular (new worsening nephropathy...
with the European Association for Study of Diabetes (EASD).
Severe hypoglycemia may increase the risk of a poor outcome in patients with type 2 diabetes assigned to an intensive glucose-lowering intervention. We analyzed data from large study glucose lowering explore relationship between severe and adverse clinical outcomes.
There are limited data regarding whether albuminuria and reduced estimated GFR (eGFR) separate independent risk factors for cardiovascular renal events among individuals with type 2 diabetes. The Action in Diabetes Vascular disease: preterAx diamicroN-MR Controlled Evaluation (ADVANCE) study examined the effects of routine BP lowering on adverse outcomes We investigated urinary albumin-to-creatinine ratio (UACR) eGFR 10,640 patients available data. During an average 4.3-yr follow-up, 938...
Abstract Aim To compare the effects of combining liraglutide (0.6, 1.2 or 1.8 mg/day) rosiglitazone 4 mg/day (all n ≥ 228) placebo ( = 114) with glimepiride (2–4 on glycaemic control, body weight and safety in Type 2 diabetes. Methods In total, 1041 adults (mean ± sd ), age 56 10 years, 82 17 kg glycated haemoglobin (HbA 1c ) 8.4 1.0% at 116 sites 21 countries were stratified based previous oral glucose‐lowering mono : combination therapies (30 70%) to participate a five‐arm, 26‐week,...
In the Action in Diabetes and Vascular Disease: Preterax Diamicron Modified Release Controlled Evaluation (ADVANCE) factorial trial, combination of perindopril indapamide reduced mortality among patients with type 2 diabetes, but intensive glucose control, targeting a glycated hemoglobin level less than 6.5%, did not. We now report results 6-year post-trial follow-up.We invited surviving participants, who had previously been assigned to perindopril-indapamide or placebo standard control...
STUDY OBJECTIVE--To assess the effectiveness of inhibition angiotensin converting enzyme in preventing diabetic nephropathy. DESIGN--Randomised follow up study normotensive diabetics with persistent microalbuminuria (30-300 mg/24 hours) treated enalapril or its matched placebo for one year. Double blind first six months, single last months. SETTING--Diabetic clinic tertiary referral centre. PATIENTS--Treatment group and each comprised 10 microalbuminuria. INTERVENTIONS--Treatment was given...
To examine the efficacy and safety of adding once-daily glucagon-like peptide-1 receptor agonist (GLP-1RA) lixisenatide to established basal insulin therapy alone or together with metformin, in people type 2 diabetes elevated glycated hemoglobin (HbA1c).We conducted a double-blind, parallel-group, placebo-controlled trial. Patients (n = 495) but inadequate glycemic control were randomized add 20 μg placebo for 24 weeks. Basal dosage was unchanged except limit hypoglycemia. HbA1c reduction...
BP is an important determinant of kidney disease among patients with diabetes. The recommended thresholds to initiate treatment lower are 130/80 and 125/75 mmHg for people diabetes nephropathy, respectively. We sought determine the effects lowering below these currently on renal outcomes 11,140 who had type 2 participated in Action Diabetes Vascular disease: preterAx diamicroN-MR Controlled Evaluation (ADVANCE) study. Patients were randomly assigned fixed combination perindopril-indapamide...